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Abstract 
 
Most of the current cancer treatments lack specificity in killing cancer cells, causing 
severe negative effects to normal cells in the body. It has previously been discovered 
that Apoptin, a protein derived from Chicken Anemia Virus (CAV), has the ability to 
selectively kill cancer cells without affecting normal cells. This tumor-specific killing has 
made Apoptin a subject of much interest and speculation. On the structural level, 
Apoptin has Nuclear Localization Sequence (NLS) on the C-terminal end with Nuclear 
Export Sequence (NES) on the N-terminal end. Interestingly, the N-terminal NES 
overlaps with the domain for multimerization. Our study focuses on uncoupling the two 
domains in order to understand the role that each of them play to induce apoptosis in 
cancerous cells. The first approach in this study involved constructing mutations that 
ablated the NES sequence in order to test for retention of functional multimerization. 
The second approach involved transfection of a separate set of mutants that preserve 
NES activity into cancer cells in order to determine whether there is a loss of 
multimerization. A better understanding of the mechanism of Apoptin’s activity in 
cancerous cells can help establish the necessary steps to be implemented in 
developing the protein as a feasible cancer treatment in the future. 
  
4 
 
Introduction 
Cancer Cells vs. Normal Cells 
Cancer is a common occurrence in life, especially in older humans and animals. 
Generally, cancer cells may have mutated “self” markers; these cellular signals are 
used by the body’s immune system to identify foreign cells and invaders, and once 
recognized as foreign, lymphocytes will destroy them (1). However, there are two types 
of cancer cells which go undetected by the body’s defenses. The first kind causes 
benign tumors where the cells closely resemble and may function like normal cells and 
stay localized to the organ or blood vessel in which the cancer cells originated from, and 
become surround by a fibrous tissue. For this reason, a person’s chance at survival is 
very high since it is easy for a surgeon to target the mass (2).  
In contrast, cancer cells creating malignant tumors are less differentiated and contain 
mutated DNA which allows them to be immortal and undergo unlimited cell divisions, as 
seen in Figure 1. Normally, a cell can activate DNA damage repair and if that fails, the 
cell will initiate apoptosis in order to kill the damaged cell. Some cancer cells, however, 
contain higher concentrations of a protein, called survivin, that inhibits apoptosis. The 
malignancy is related to altered cell-cell interactions. Two factors contribute to the 
relentless growth of cancer cells. First, they lack the feature in which normal cells are 
able to sense when their population becomes crowded and stop dividing, called contact 
inhibition. Second, cancer cells do not need growth factors to complete the cycle that 
initiates cell division. In normal cells, the protein cyclin combines with a kinase creating 
a protein complex, and in the presence of growth factors, causes the metabolic reaction 
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that initiates cell division to occur. Mutations in cancer cells uncouple or reduce the 
necessary signal transduction stimulation from the growth factor chemicals (1).  
 
Figure 1: Visual difference between benign tumors and malignant tumors (3). 
Cancer cells have additional mechanisms that make them very efficient at using the 
body’s resources to facilitate their unrestrained growth. Cancer cells do not anchor 
themselves on neighboring cells and therefore, can metastasize, meaning the 
tumorigenic cell travels through the body and affects another organ. Once the cancer 
cells stray from the initial tumor, they will reach the basal lamina, which is the 
membranous barrier that surrounds organs and blood vessels. Normal cells are unable 
to penetrate this membrane, but cancer cells often possess elevated levels of cell 
surface receptors specific to proteins that produce enzymes which can degrade the 
basal lamiae. Many cancer cells also secrete the protease called plasminogen activator, 
causing increased protease activity in normal serum in order to assist the cancer cells 
invade the membrane (2). This event can also occur at the primary tumor site, allowing 
the cancer cells to invade the tissues which they mutated from. Furthermore, tumors 
display angiogenesis, in which the cell can induce new blood vessels to form. Many 
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tumor cells can initiate this process by secreting growth factors which they naturally 
produce, while others can somehow induce surrounding normal cells to secrete such 
chemicals. The blood vessels nourish the tumor allowing it to grow in size, and also 
increase the probability of additional harmful mutations as well as the possibility of 
metastasis. Thus, malignant cancer is very dangerous because the uncontrolled growth 
can stifle normal cells causing cell death and organ failure.  
Cancer arises from mutations; if only one mutation is necessary to transform a normal 
cell into a carcinoma, then the incidence of cancer would be independent of age which 
is clinically untrue. The probability of cancer rises exponentially with age. Therefore, 
cancers arise through the process of clonal selection in which one mutation would give 
a cell a slight growth advantage. Within its progeny, other mutations would arise to 
increase the uncontrollable growth, and in another generation, a mutation would give 
the cell the ability to outgrow other cells. Its progeny would then form a mass of cells, 
and contain these three mutations. Consequently, there is a “multi-hit” model for the 
process of mutations that allow cancer to originate, which also explains why the 
incidence of cancer increases with age (2).  The mutation can also morph a cancer 
cell’s form making it appear very different from the normal cell morphology as seen in 
Figure 2. The cancer cells appear jagged with a small cytoplasm which encloses 
enlarged, sometimes multiple nuclei containing course chromatin. On the contrary, 
normal cells have a smooth, circular morphology with a large cytoplasm, and a single 
nucleus containing fine chromatin.  
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Figure 2: The difference between normal and cancer cells structure (4). 
 
Tumor suppressor genes 
 
Tumor suppressor genes are involved in inhibiting unwanted cell proliferation, thereby 
suppressing tumor formation. Retinoblastoma (RB) and p53 are the most widely known 
tumor suppressor genes.  
The RB gene prevents cells from entering S phase during the cell cycle. Transcription 
factors called E2F are involved in transcription of proto-oncogenes like c-myc and c-fos 
This transcription is essential for initiating mitosis. When unphosphorylated, the RB 
protein binds to E2F preventing its association with the promoters of c-myc and c-fos. 
As a result, cell cycle is stopped and cell proliferation is inhibited (28). 
p53, on the other hand, begins its action when DNA is damaged. p53 either  halts cell 
division if DNA has sustained minor damage or triggers the cell to induce apoptosis if 
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DNA has sustained major irreparable damage. The p53 protein is made up of 393 
amino acids with three functional domains: a C-terminal domain, an amino N-terminal 
domain and a central DNA-binding domain. The DNA binding domain interacts with 
promoter regions of target genes. 
Under conditions with serious DNA damage, p53 induces apoptosis through 
mitochondria-dependent ROS generation. However, loss of its tumor suppressing ability 
is a common occurrence in cancers. Gene mutation of p53 under oxidative stress can 
cause it to be functionally inactive. It is proposed that p53 is functional for its DNA 
binding and transcriptional ability only in its reduced state. Hence, redox modification of 
cysteine and tyrosine residues in its DNA binding domain can have direct effects on 
transactivation potential of p53 (28).  
Such widespread occurrence of p53 mutation in cancers is a major hurdle in the 
development of anti-cancer therapy. In this context, recognition and study of other 
possible mechanisms of apoptosis in cancer cells that rely on a p53-independent 
pathway can be an important step in the right direction.  
Cancer Treatments and Therapies 
The treatment paths available to cancer patients are not for the squeamish or self-
conscious. All options can be very painful, and possibly affect a person’s physical 
appearance.  In addition, all treatments are not guaranteed to “cure” a patient per say, 
by causing the cancer to enter into remission.  Furthermore, there are certain kinds of 
cancers that are untreatable since there is very little known about them at present.  
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Surgery 
Surgery is the oldest cancer treatment, and has multiple purposes in preventing, 
diagnosis, staging, curing, and managing the disease. It is the simple idea of removing 
the cancer from a certain part of the body. Preventative surgery can be used to remove 
tissues that are prone to develop cancer. Surgery can also be used to diagnose a form 
of cancer, and stage its progression. Curative surgery is used to remove the tumor, but 
for cancer that is highly progressed, palliative surgery can be used to remove part of the 
tumor in order to relieve discomfort or disability (5).  
Chemotherapy 
Chemotherapy uses drugs to destroy cancer cells by stopping or slowing their growth. 
This treatment allows many types of cancers and metastasized cancers to be treated, 
since the drug can travel throughout the entire body. The ability of chemotherapy to kill 
cancer cells depends on its ability to halt cell division and most treatments are p53 
dependent. Usually, cancer drugs work by damaging the RNA or DNA which codes for 
the proteins that initiate the cell to copy itself in division. If the cancer cells are unable to 
divide, they die via induction of cell suicide (self-death or apoptosis).  The drug is more 
likely to kill the cancer cells that divide the fastest, causing the tumor to shrink (6). 
However, the drug also affects healthy cells which are usually able to repair themselves, 
causing side effects. 
Radiation Therapy 
Radiation therapy is one of the most common treatments for cancer which uses high-
energy particles or waves to destroy or damage cancer cells. An external beam can be 
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aimed at the cancer using a radiation machine or the radiation can be applied to the 
cancer internally by using seeds, capsules, or ribbons containing the radioactive 
material. The radiation ionizes the bonds in the cell's water molecules releasing 
hydroxyl free radicals which attack the damaged DNA molecules causing damage, 
mutations, and sometimes even break the DNA strands. Without functional DNA, the 
cancer cells can no longer function properly and induce apoptosis (6). This treatment is 
designed to treat tumors, and may have a negative effect on healthy cells in close 
proximity to the tumor site. Usually these cells are able to repair themselves while 
cancer cells cannot. 
Immunotherapy 
Immunotherapy is a treatment that uses drugs or man-made proteins to stimulate the 
body’s immune system to fight cancer. Normally, the immune system can identify 
foreign and possibly threatening cells. However, cancer mutates from the body’s healthy 
cells, making the cellular signaling similar if not identical to the normal cells. Therefore, 
the body cannot invade these cells nor can these cells repair the mutation like normal 
cells would. The two main ways that immunotherapy can be done are by boosting the 
patient's own immune system or by providing man-made versions of normal parts of the 
immune system. However, this treatment is still in the early stages of development (5). 
For example, the drug Avastin uses monoclonal antibodies, where an intravenous 
humanized mAb attaches to receptor proteins on cancer cells and blocks the pathway 
involved in new blood vessels formation. By preventing angiogenesis, the tumor is 
inhibited in its growth. Avastin has only been approved for treatment of kidney cancers 
so far (5).  
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Developing Therapies 
There are always new ideas developing for ways to treat, manage, and cure cancer 
since a portion of government and private funding go to cancer research each year. 
However, many of these are still in the research stage. For example, targeted therapy is 
a newer type of cancer treatment that uses drugs or other substances to more precisely 
identify and attack cancer cells, usually while causing little damage to normal cells. 
Another example is hyperthermia which uses heat to treat cancer, and with the 
development of newer tools, the technique is being studied for use against many types 
of cancer. Furthermore, there is the budding idea of stem cells and bone marrow 
transplants which will allow regeneration of the tissues affected by cancers. Yet, there is 
not enough evidence to support the theory at present.  
Side Effects and Downfalls 
As mentioned previously, all treatments can produce side effects, and possibly affect 
healthy cells in a patient’s body. More importantly, each patient will respond differently 
to each treatment. Each type of cancer will also be affected differently by different 
treatments. Unfortunately, the most effective cancer treatments are aggressive and can 
have more than desirable side effects. For instance, chemotherapy can affect healthy 
cells and cause side effects such as nausea, low blood cell counts, hair loss, mouth 
sores, and pain. Radiation therapy can also have adverse effects like fatigue, skin 
problems, nausea, swelling and hair loss in the treated area. There are also multiple 
risks of complications during surgeries which could even lead to death. Even though 
there are other less aggressive therapy options that help slow down the progression of 
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cancer and have less negative effects on the person’s body, they tend to have a low 
success rate of putting the cancer into remission.  These less aggressive therapies are 
usually used to increase quality of life of patients, not prolong their life, since cancer 
itself can be very debilitating. Another pitfall to all of these treatments is that sometimes 
they are the most effective in combination in some patients, making the medical cost 
highly expensive. There are always new clinical trials emerging with new cancer 
treatments and therapies, but these are not the safest options because the possible 
side effects are not truly known until multiple trials are run (5). 
Looking Toward the Future 
The need for a better cancer treatment is the conventional subject of research for many 
scientists today. Cancer is on the top of the list, second only to heart attacks, for main 
causes of death in the United States. For such a devastating disease, funding for 
research is scantly provided, even when some of the applications are very promising to 
highly increase the survival rate of cancer patients. The hurdle lies in the reason that the 
drug companies are to be provided with enough evidence supporting the theory for 
creating a pharmaceutical regimen before they would decide to invest in the setup of a 
laboratory dealing with the research. One of such promising research has been on the  
Chicken Anemia Virus (CAV). CAV can selectively kill cancer cells without having an 
effect on normal cells. Therefore, everything there is to know about its mechanism to kill 
cancer cells must be investigated before it can be proposed as a potential cancer 
therapy. Once enough evidence is established in favor of the research, the mechanism 
of CAV could eventually be implemented to create a very successful targeted therapy 
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that uses drugs to seek and invade cancer cells inside the body, with no negative 
effects on the patient’s healthy cells. 
Chicken Anemia Virus 
The chicken anemia virus (CAV) is a small animal circovirus from the family Circoviridae 
and genus Gyrovirus. Like other viruses in the Circoviridea family, CAV contains a small 
circular, single-stranded DNA genome. The virus was first discovered when studying a 
Marek’s disease outbreak and was isolated from young chickens. In these animals, the 
virus causes anemia, lymphoid depletion and hemorrhaging which increases mortality. 
When the virus was studied, it was determined that the CAV genome contains three 
partially overlapping open reading frames (ORFs) that may code for certain peptides 
(Figure 3). Experiments displayed evidence that the genome contains only one major 
start sequence for RNA transcription and one polyadenalation site, but contains multiple 
promoter regions responsible for regulating CAV transcription. The CAV promoter-
enhancer region contains a TATA box that is believed to be the RNA polymerase II 
transcription factor-binding sequence element. Furthermore, the region contains 5 exact 
repeats, and data that has been collected indicated that cells that contained a mutation 
deleting one of these repeats displayed cells that were less sensitive to the CAV virus. 
This further indicates that there are multiple enhancer elements necessary for optimal 
CAV replication. The virion contains a single strand of the minus DNA, but cells infected 
with CAV also contain a double stranded form involved in replication. The preceding 
evidence suggests novel genome organization and expression in the small virus. 
Compared to other known animal circoviruses such as porcine circovirus (PCV) and 
Beak and feather disease virus (BFDV), CAV has the largest genome, and according to 
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studies by Crowther et al., the structure is more complex than the others when observed 
through cryomicrographs (Figure 2). The study indicates that the capsid protein in CAV 
responsible for encapsidation also has a role in replication (8). It was discovered in the 
early 1990’s that the VP3 gene located within the CAV genome that codes for a protein 
named Apoptin, was proven to have the ability to selectively kill cancer cells. However, 
there is still a lot unidentified about CAV since it is a complex circovirus. 
 
 
 
Figure 3: Genomic map of Chicken anemia virus (9). 
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Figure 4: Three dimensional maps of CAV (A), PCV-2 (B), and BFVD (C) composed 
from crymicrographs (8).  
 
Overall structure of Apoptin 
 
First isolated in Japan, CAV is a small non-enveloped virus containing a single, minus-
strand circular DNA of size of approximately 2.3 kb . CAV has open reading frames 
(ORFs) only on the antigenomic strand. Interestingly, the arrangement of ORFs in CAV 
bears great resemblance to that of torque teno virus (TTV). They tend to bear more than 
80% similarity near the replication origin without having much similarity in the nucleotide 
sequences of remaining genome. The major transcript of CAV is a polycistronic 
unspliced mRNA with three overlapping ORFs that are responsible for encoding three 
different proteins. CAV encodes the structural protein with the replicase domain at 
frame 1 and a nonstructural protein with a phosphatase domain at frame 2. The protein 
on frame 2 is responsible for inducing apoptosis in transformed cells. These proteins 
are named VP1, VP2 and VP3 respectively (11). VP1 is a 51- kDa capsid protein, VP2 a 
24-kDa dual specificity phosphatase and VP3 a 14-KDa non-structural protein (10). 
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Mechanism of induction of programmed cell death 
 
To understand more about induction of apoptosis by VP3, it is important to know about 
its mediators. Cysteine proteases, called caspases serve as initiators and executioners 
of the apoptotic process. Caspases are activated by two signaling pathways – the 
extrinsic death receptor and the intrinsic mitochondrial pathway. In the extrinsic 
pathway, initiator caspase-8 and adaptor FADD are recruited into a complex that 
induces cell death as a result of ligation of death receptors by their ligands. On the other 
hand, release of cytochrome c into the cytosol caused by proteins of the Bcl-2 family 
initiates the mitochondrial pathway. Cytochrome c eventually binds to the adapter 
protein Apaf-1 activating caspase-9 in apoptosome in return. Both pathways, however, 
converge downstream during the activation of effector caspases, leading to cell death 
by cleavage of cellular substrates. Interestingly, even though apoptin expression results 
in the activation of caspases, apoptin-induced cell death is not dependent on death 
receptors. It has been established that cells deficient in extrinsic pathway mediators, 
FADD or caspase-8, are still sensitive to apoptin. On the contrary, apoptin-mediated 
apoptosis is affected by mitochondrial pathway mediators like Apaf-1 (13).  
There are specific mechanisms employed by Apoptin in inducing apoptosis. 
Understanding the details of its structural components enables us to see how those 
mechanisms are operated. Apoptin has a shuttling mechanism that is vital for its 
apoptotic property.  Shuttling refers to the tendency of Apoptin to be partitioned in the 
nucleus in transformed cells while staying in cytoplasm in normal cells (14).  
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Interactions of Apoptin 
 
There are many theories regarding how Apoptin kills cancerous cells. One of such 
theories involves an apoptosis-related cysteine protease called Caspase 3 (CASP3) 
that is believed to catalyze the proapoptotic activation of CDK2. A study also showed 
that Apoptin-induced apoptosis was reduced in MCF7 cells that lack CASP3 activity. 
This further emphasized the role of CASP3 in apoptosis (17).  
Even though the mechanism by which Apoptin kills cancer cells is not very clear, the 
fact that nuclear localization is an essential primary step in apoptosis is well established. 
Apoptin’s interaction with specific cellular factors or its specific posttranslational 
modifications could be a key in subcellular localization in normal and tumor cells (17). 
However, this targeted localization of Apoptin in the nucleus of tumor cells is not 
sufficient enough to induce apoptosis. In fact, targeted expression of Apoptin in the 
nucleus of normal cells does not initiate apoptosis which further supports that nuclear 
localization alone is not sufficient for apoptosis. This is where the possibility of its 
interaction with specific cellular factors, proteins and/or its further modifications comes 
into play. It has been demonstrated that through its proline-rich region, Apoptin interacts 
with the regulatory subunit of phosphoinositide 3-kinase (P13-K) called the SH3 domain 
of p85. This activation is supposedly essential for apoptosis induction as Apoptin 
derivatives lacking the proline-rich region are unable to activate PI3-K leading to 
diminished apoptosis. Interestingly, Apoptin mutants containing the proline-rich region 
are found to be sufficient enough to cause this interaction and induce apoptosis in 
return (18).  
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It has also been shown that Apoptin associates with the anaphase-promoting complex 
(APC) where APC1 is recruited to the promyelocytic leukemia (PML) nuclear bodies 
(NBs) inducing G2/M arrest and eventually apoptosis. APC, also known as the 
cyclosome or APC/C, is comprised of 11 proteins which serve the function of guiding 
the cell through mitosis by organizing ubiquitination of regulatory proteins and targeting 
them for destruction in the proteasome (17).  In one of the studies, APC3 (also known 
as Cdc27) was observed to co-localize with wild type Apoptin in the nucleus of 
transformed cells. However, no such effect was observed in case of Apoptin mutant. 
This result is in cohesion with the fact that only wild type Apoptin is successful at 
associating with APC/C and inducing apoptosis. The same study also suggested the 
presence of Apoptin in PML bodies. Because of their association as mentioned earlier, 
APC/C would be expected to be present in PML bodies. It was shown that along with 
Apoptin wildtype and Cdc27, CFP-PML also co-localized in the nucleus of transformed 
cells. The association of Apoptin with APC/C results in degradation of several APC/C 
subunits including Cdc27 and APC1. Degradation of such mitotic checkpoints is 
associated with apoptosis (19).  
Nuclear Localization Sequence and Nuclear Export Sequence 
 
Apoptin is made up of 121 amino acids. There are two sequences contained in Apoptin: 
Nuclear Localization Sequence (NLS) and Nuclear Export Sequence (NES). NLS1 and 
NLS2 encompass amino acids 82-88 and 111-121 respectively. NES encompasses 
amino acids 97-105. Similarly, a short hydrophobic leucine-rich sequence (aa 33-46) is 
required for self-association and binding of other interaction partners. Another important 
aspect of the structure to be noted is that via the interaction of the proline-rich 
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hydrophobic regions in the N-terminus (aa 1-69) of each monomer, the formation of 
multimeric complex is rendered possible (12). 
Multimerization 
 
Apoptin can spontaneously form non-covalent globular aggregates of about 30-40 
subunits by a strong and virtually irreversible process of multimerization. When 
expressed in living cells, Apoptin has been found to exist in large complex forms in vivo. 
It was observed that Apoptin multimers lack internal ordering and hence a clear 
secondary structure. However, Apoptin multimers, with at least a partially ordered 
surface, are considered sufficient enough for the interaction with cellular factors. Such 
interactions, in turn can induce apoptosis in tumor cells (16).  
In a study involving recombinant MBP-Apoptin, its chemical cross-linking did not affect 
subcellular localization and eventually apoptosis-inducing ability in human tumor cells. 
Also, cross-linked multimers did not show any effect in normal cells.  
It was concluded that Apoptin, either aggregated or multimeric, contains the ability to 
induce apoptosis in a tumor-specific way in vivo. Hence, Apoptin does not have to adopt 
a monomeric form to show its activity as a tumor-specific apoptosis inducing protein but 
is required in conjunction with nuclear localization (16). 
How is Apoptin different? 
 
One of the most promising aspects of Apoptin as an anti- cancer therapy is its 
implementation of p53- independent pathway in invading cancer cells. p53 is an anti-
tumor protein that acts an  essential apoptotic signal being mediated for exerting anti-
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cancer effect. It serves an important function as a growth checkpoint which protects 
against accumulation of mutations and prevents cellular transformation caused by 
activation of oncogene (24).   
Even though the levels of p53 are usually low due to its short half-life, its activation can 
be induced by stress signals via different mechanisms. UV irradiation and 
chemotherapeutic drugs can cause p53 to stabilize and activate via covalent 
modification where transactivation domain is phosphorylated and allosteric control 
region is both phosphorylated and acetylated. Most cancers have either deleted or 
mutated forms of p53 causing it to be functionless. It is disrupted in roughly 50% of all 
human tumors (24).  
Osteosarcoma cell lines synthesizing either wild-type 53, mutant p53 or no p53 were 
studied in the study conducted by Zhyang et al where Human osteosarcoma cell lines 
U2OS (wildtype p53), Saos-2/alal43 mutant p52) and Saos-2(no p53) were transiently 
transfected with plasmid DNA pCMV-VP3 that is responsible for encoding Apoptin. It 
was observed that Apoptin was able to induce apoptosis in human tumor cells even 
when no p53 was involved. In addition to Saos-2 cells, p-53 negative human hepatoma 
(Hep 3B cells) were also investigated for the effect of Apoptin. Surprisingly, Apoptin 
efficiently induced apoptosis in this case as well (25). 
 Premises of the Following Study 
 
Apoptin holds the key to a promising and innovative approach to cancer treatment and 
therapy due to the characteristics discussed. However, all the premises associated with 
the protein’s anti-cancer behavior need to be assessed before addressing the possibility 
21 
 
of a drug design. The mechanisms of nuclear export and multimerization are believed to 
be very important in cancer selective killing. One of the studies used two NES 
derivatives, Ap-pmNES and Ap-RevNES, in a coimmunoprecipitation assay to analyze 
their ability to multimerize (19). As compared to the wildtype Apoptin, the Ap-pmNES 
showed a reduced ability to interact with Flag-Apoptin, and Ap-RevNES, which has a 
functional NES, was unable to interact with Flag-Apoptin. The study also showed that 
Ap-pmNES was less effective than the wildtype in mediating trans localization reflecting 
decreased multimerization activity (19).  The results suggested that the genetic regions 
that code for nuclear export and multimerization in Apoptin are overlapping as shown in 
Figure 5 (19). Therefore, our study has been designed to make mutations to this region 
in an attempt to ablate one of these mechanisms while preserving the other’s function. 
According to the studies performed by previous groups, the mutants ApI37A and 
ApI40A have a non-functional NES while ApT43A and ApL44A retain nuclear export 
(29). 
 
 
 
 
 
 
 
Figure 5: Genetic map of the Apoptin protein.  
NES / Multimerization Domain NLS 
(Wildtype Apoptin)  I  A  G  I  T  I  T  L  S  L 
(ApI37A)                   A  A  G  I   T  I  T  L  S  L 
(ApI40A)                    I  A  G  A  T  I  T  L  S  L 
(ApT43A)                   I  A  G  I  T  I  A  L  S  L 
(ApL44A)                    I  A  G  I  T  I  T  A  S  L 
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Materials and Methods 
 
Plasmid Preparation 
 
The mutant Apoptin must be contained in both the pGBK and pACT2 vectors in order to 
perform the Yeast 2 Hybrid assay. The mutations were made while the protein was 
contained in the pGBKT7 vector. Therefore, a restriction digest was performed to excise 
the mutants ApI37A and ApI40A from the pGBKT7 vector. The fragments were excised 
precisely using NCO1 and BamH1 enzymes in Buffer E. The pACT2 vector was cut 
using same enzymes so that the insert would fit into the restriction sites of pACT2 
during the ligation. The digests were run for approximately an hour on a 0.9% agarose 
gel to separate insert from cut vector, and separate the cut pACT2 vector from uncut. 
Following electrophoresis, the gels were stained in an ethidium bromide solution in a 
shaker for approximately15 minutes followed by washing with TAE buffer. The 
restriction products obtained at the bottom of the gel were then excised and stored in 
eppendorf tubes in the freezer. 
The kit components of Gene Clean® and procedure were used to purify the mutant 
Apoptin and vector DNA from the agarose gel. The gel was suspended in 2 volumes of 
sodium iodide solution, which is a chiaotropic salt that will keep the agarose melted after 
a  55 degree incubation. This was followed by addition of about 15ul of glassmilk slurry, 
which is positively charged to bind DNA. Finally, the pellets obtained from this 
procedure were washed with New Wash buffer in order to wash off the unwanted 
residues without eluting the DNA off of the glass. 
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After purification, ligation was carried out to insert the genes of insert into the pACT2 
vector. Two setups were implemented – one with 2ul of vector and 6ul of insert and 
another with 1ul of vector and 8ul of insert. A negative control containing only vector 
was also run. These samples were incubated in room temperature for one hour.  
Following the incubation, transformation was carried out in accordance with the 
standard protocol. 4ul of ligation along with 42ul of competent E.coli was used for each 
sample. The final samples were plated on LB+ Ampicillin plates. The plates were then 
incubated at 37 degree overnight.  
The colonies obtained from the plates were inoculated into LB+ Ampicillin broth and left 
overnight in the shaker. After implementing the technique of colony PCR to detect 
positives, the putative positive cultures were used for plasmid preparation in accordance 
with the standard protocol. This procedure of plasmid preparation allows us to purify the 
plasmid DNA from E.coli. 
Fluorescence microscopy 
H1299, which are non-small cell lung carcinoma cells, were cultured on cover slips for 
24 hours and transfected using Effectene from Qiagen in accordance with the standard 
protocol. 24 hours later, the cells were washed with PBS and fixed with 2% 
paraformaldehyde in PBS on the shaker for approximately 15 minutes. After washing 
the cells with PBS again, they were mounted onto the slides containing the appropriate 
mounting media. The cells were imaged by fluorescence microscopy the next day. 
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Results 
Vector transformation 
 
 It was previously proposed by our group that there are five amino acid residues I37, 
I40, T43,  L44, L46 that are most conserved. Hence, they are most likely to have an 
effect on nuclear export and multimerization when mutated (29). Previously, the 
mutations ApI37A and ApI40A were ligated into a plasmid vector, pGBKT7. All of these 
mutations were also truncated by the removal of NLS domain and ligated into a GFP 
expression vector. Experiments demonstrated that the mutations ApI37A and ApI40A 
were deficient in nuclear export. Therefore, these two mutants were assumed as 
promising candidates to perform the Yeast 2 Hybrid assay in order to determine if there 
is retention of multimerization in the absence of nuclear export. 
A Yeast 2 Hybrid assay employs two vectors. The pGBKT7 vector contains a DNA 
binding domain (DBD), which forms a part of essential transcription factor to turn on 
Gal4 promoter and the pACT2 vector contains the transactivating domain (TAD) which 
binds to RNA polymerase II to initiate transcription. By bringing these two vectors in 
close proximity, a protein-protein interaction is expected that leads to recruitment of 
RNAPII to Gal4 promoter. This will eventually result in transcription of LacZ gene 
resulting in blue colonies in -Leu/-Trp plates. In the past experiments, when performing 
the Yeast 2 Hybrid assay, pACT2 vector containing wildtype Apoptin was used which 
yielded false positives (29). For this reason, it was speculated that using the two vectors 
with mutant Apoptin would eliminate false positives. Therefore, the mutant Apoptin was 
required to be transformed into the pACT2 vector. 
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 As the first step, restriction of these mutations with enzymes BamH1 an Nco1 was 
carried out. The mutant inserts were then excised from the vector via gel 
electrophoresis as seen in Figure 1. In the figure, lane 1 was loaded with DNA marker 
for determination of fragment sizes obtained in other lanes. Lanes 3 and 4 were loaded 
with restricted mutant ApI37A. The restricted products visible at the bottom of the lanes 
correspond to fragment sizes of mutant insert ApI37A. Comparing the sizes with the 
marker, they were observed to be approximately 1kbp. Similarly, lanes 7 and 8 were 
loaded with restricted mutant ApI40A. The restriction products at the bottom of the lanes 
correspond to fragment sizes of mutant insert I40A, which were also observed to be 
approximately 1kbp in size. Following gel electrophoresis, purification of these insert 
mutants were carried out in order to prepare mutant DNAs for further manipulation like 
ligation into pACT2 vector. 
To prepare the recipient vector for the previously prepared mutant DNAs, pACT2 vector 
was successfully restricted using enzymes BamH1 and Nco1 as well. As seen in Figure 
2, Lane 1 was loaded with DNA marker while lanes 3, 5, 7 and 9 were loaded with 
restriction digests containing parent vector only, parent vector with Nco1 only, parent 
vector with BamH1 only and parent vector with both the enzymes respectively. Lanes 
3,5 and 7 were used as controls to assess the activity of enzymes on the vector. There 
are two obvious bands observed in lane 3 which corresponds to the uncut state of the 
vector since no enzymes were used for the control in lane 3. Lane 9 clearly shows only 
one band, corresponding to cut state of the vector. The fragment was observed to be at 
approximately 8kbp after being compared to the marker. The excised portion of vector 
from lane 9 was used for ligation purposes. 
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A ligation was then performed to insert mutant DNAs into pACT2 vector. In order to 
amplify the ligation product and screen for successful clones, transformation into E.coli 
was carried out. Ampicillin plates were used for plating transformation products because 
vector pACT2 is established to be resistant to Ampicillin if successfully ligated with the 
mutant inserts. A negative control containing only vector was also set up. After the 
incubation, the plates for both mutations displayed several white colonies. However, 
many colonies were also observed on the negative control plate in the first few trials. 
This consequence was attributed to possible vector background, meaning the vector 
ligated upon itself without encompassing the insert, which could have been resulted 
from incompletely cut pACT2 vector during its restriction digest. Hence, to minimize this 
impact, several rounds of ligation and transformation were carried out after allowing 
pACT2 vector restrictions to run for almost 3 hours. This change was observed to yield 
favorable results by reducing the number of colonies on the negative plate substantially.   
Nevertheless, there were still many colonies on each of the plates. In order to rapidly 
detect positive colonies on the plates, the technique of colony PCR was implemented. A 
number of positive colonies was detected for both mutations. Experiments are currently 
in progress to confirm these putative positive colonies by inoculating them overnight 
followed by the technique of plasmid preparation and restriction of the products in order 
to visualize if the vector contains an insert, which will be obvious via gel electrophoresis.  
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Fluorescence microscopy 
As an alternative approach, mutations ApT43A and ApL44A were used to study 
multimerization by observing the localization of the protein in vivo. It was previously 
determined by our group that compared to GFP alone, GFP-ApT43A and GFP-ApL44A, 
showed an obvious cytoplasmic localization. This result was consistent with the 
presence of a functional NES in these mutants (29).  In our experiments, these mutants 
were used alongside dsRed Apoptin Wild Type (ApWT) to assess the retention of 
multimerization in them, which would be indicated by their co-localization with ApWT in 
the nucleus. Therefore, both the mutant and the wild type Apoptin were used to co-
transfect non-small cell lung carcinoma cells called H1299 cells, which have been 
established as a model for the study of CAV. Using confocal fluorescence microscopy, 
the localization of these mutants was visible. Mutants GFP-ApT43A and GFP-ApL44A 
were observed to be co-localized in the nucleus with dsRed-ApWT as seen in Figures 3 
and 4, respectively. In these figures, DAPI shows location of nuclei by staining them 
blue. Hence, from the observation of both of these figures, the migration of GFP and 
dsRed into the nucleus is demonstrated. Even though some portion of the mutants 
appeared to be diffused in the cytoplasm, they were predominantly co-localized in the 
nucleus. These results allow us to propose that in the presence of wild type Apoptin, the 
Apoptin mutants were able to migrate into the nucleus indicating the retention of 
multimerization. Thus, our data suggests that mutants ApT43A and ApL44A do not play 
a role in either nuclear export or multimerization of Apoptin.  
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Discussion  
 
Apoptin is a protein that is translated in the circovirus known as the Chicken Anemia 
Virus (CAV). As previously discussed, Apoptin can selectively kill cancer cells without 
affecting normal cells, and can induce apoptosis in these tumorigenic cells independent 
of the p53 pathway.  Cancer can arise from many different mutations in the regulatory 
proteins that cause cells to become immortal and proliferate uncontrollably. 
Nevertheless, Apoptin has been proven to induce apoptosis in multiple cell lines, 
meaning that it can be used to treat multiple cancers. It is also evident that Apoptin can 
accurately distinguish between cancer cells and primary cells through some cellular 
signal marker, which accounts for its distinct tumor-selective ability to induce apoptosis. 
There are two mechanisms used by Apoptin that are most likely to be involved in cancer 
selective killing: nuclear export and multimerization. Nuclear export causes the protein 
to shuttle in and out of the nucleus in both tumorigenic and primary cells. However, in 
primary cells, Apoptin is concentrated in the cytoplasm while it becomes localized in the 
nucleus in cancer cells. Another important difference that has been observed is that the 
protein remains diffused in primary cells and becomes punctate in the cancer cells. 
Multimerization is the second mechanism which involves the protein forming large 
multimers as it localizes. Once the units become larger than a dimer, they tend to have 
difficulty shuttling in or out of the nucleus. The sequence that codes for multimerization 
overlaps with the NES domain.  Hence, it is complicated to understand the role that 
each mechanism plays when both remain functional.  
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Mutations 
The previous groups worked to prepare the mutations ApI37A, ApI40A, ApL43A, and 
ApT44A. The study looked at the Nuclear Export Sequences (NES) of multiple proteins 
and noticed that Isoleucine-37, Isoleucine-40, Leucine-43, and Tyrosine-44 were 
conserved in many of these proteins. Therefore, it was speculated that these residues 
are important in NES functionality, causing them to create point mutations at these 
positions. These residues were mutated with an alanine due to its neutral charge, non-
polar side chains, and small size in order to avoid any significant change in the protein’s 
conformation or structure. According to the studies these groups performed, it was 
determined that mutations ApL43A and ApT44A retain nuclear export while mutations 
ApI37A and ApI40A are deficient in it. Therefore, it can be conjectured that the 
Isoleucine residues have a more significant function in the proper functioning of nuclear 
export than the Leucine and Tyrosine residues. According to the experiments we did 
with the mutations ApL43A and ApT44A, these residues are not important in the 
multimerization function since both the mechanisms of nuclear export and 
multimerization were retained.  This conclusion was made based on the confocal 
microscopy images that displayed both the mutant Apoptin tagged with GFP and the 
wildtype Apoptin tagged with dsRed to be co-localized in the nucleus, thereby indicating 
that the two proteins formed multimers. If the process of multimerization was disrupted 
by the mutations, the mutant Apoptin would be localized in the cytoplasm since NLS is 
non-functional, while the wildtype Apoptin remained in the nucleus. Consequently, the 
mutants ApL43A and ApT44A contain mutant residues that are not important in either 
nuclear export or multimerization, meaning the two mechanisms were not uncoupled. 
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However, these results could be ambiguous if the intact multimerization function of the 
wildtype Apoptin is able to initiate the formation of a multimer with the mutant protein. 
There seems to be a possibility of this in the confocal fluorescence images where there 
is residual mutant Apoptin observed in the cytoplasm even though they are 
predominantly located in the nucleus. 
Also, further testing on the mutants ApI37A and ApI40A still needs to be performed to 
determine whether multimerization is retained by the mutant Apoptin since previous 
studies have proven that nuclear export is, in fact, ablated in them. 
Relationship between NES and Multimerization 
Due to these results, it appears that the NES and the multimerization domains may be 
very tightly overlapping, causing it to be challenging to uncouple these mechanisms. 
The previous mutations were induced at the residues that were discovered to be 
conserved in the NES of multiple proteins. Thus for future experiments, it is advisable to 
induce mutations alternatively at the residues that are not established to be involved in 
the NES. This can enable us to create a mutant Apoptin containing a functional NES 
without retention of multimerization. The possibility of the two domains being overlapped 
in such a way that when one is ablated, both mechanisms become non-functional can 
only be addressed if multiple varied mutations are induced. 
In addition, the extent of multimerization has also been shown to vary between different 
cell types, where primary cells are predisposed to higher level of multimerization (19). In 
this context, it seems important that further research be performed in determining the 
role of multimerization in Apoptin’s anti-tumor behavior. Further studies and 
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experiments need to be conducted in order to assess the role of varying levels of 
multimerization by creating mutations with complete and partial elimination of 
multimerization domains. 
Mobilization of Apoptin in Cancer Cells vs. Normal Cells 
Due to evidence from previous studies on Apoptin, it seems that nuclear export and 
multimerization are associated and are important in the process of inducing cancer cell 
death. Conceivably, both mechanisms are needed for the protein’s selectivity and its 
ability to induce apoptosis.  However, the mechanisms appear to act differently in 
primary cells versus tumorigenic cells. For example, in primary cells the protein shuttles 
in and out of the nucleus and remains diffused in the cytoplasm, and in cancer cells, the 
protein becomes concentrated and punctate in the nucleus. For this reason, perhaps 
the key to Apoptin’s selective killing is due to some biochemical difference between 
cancer and primary cells. According to a study performed by Heilman et al, it was 
discovered that Apoptin’s solubility increases in transformed cells, while remaining 
highly insoluble in primary cells (19). Therefore, the results suggest that the increase in 
solubility corresponds with the protein’s nuclear localization in cancer cells. 
Furthermore, it can be speculated that Apoptin may be tightly associated with cellular 
filament networks which would explain the difference in solubility and mobilization within 
cancer cells and normal cells. This concept should be further investigated to determine 
what causes the biochemical anomaly to perhaps determine how Apoptin can induce 
cancer-specific apoptosis. 
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Other Mechanisms of Apoptin Involved in Inducing Cancer Cell Death 
Besides the role of the NES and multimerization domains, it is also worthy to look into 
other possible interactions and mechanisms that Apoptin could employ for localization 
and other behaviors. Some studies have suggested that human Peptidyl-prolyl 
isomerase-like 3, Ppil3, can bind Apoptin directly and also hold it in cytoplasm by 
binding to its C-terminal in some cells including tumor cells (20). The study also 
demonstrated the possible association of nucleocytoplasmic shuttling of Apoptin with 
the level of expression of intrinsic Ppil3.  It was also proposed that Ppil3 when bound to 
threonine-proline bond of Apoptin could shift its conformation causing Ppil3 to modify 
the activities of nearby NES and/or NLS (20).  
Some other studies have also proposed that ceramide signal transduction pathway is 
involved in Apoptin-induced cell death. Acid sphingomyelinase, ASMase, is believed to 
play a role in this mechanism as inhibition of ASMase showed blockage of Apoptin-
induced cell death. It was demonstrated that ASMase plays a role in generating 
ceramide via the hydrolysis of sphingomyelin which acts a second messenger signaling 
induction of apoptosis (26). 
Yet some other studies have also proposed apoptin-induced apoptosis to be dependent 
on abnormal phosphatidylinositol 3-kinase (PI3-kinase)/Akt activation, leading to cyclin-
dependent kinase CDK2 activation. This study suggested the interaction of Akt with 
apoptin enhancing the nuclear localization of Akt. Akt was observed to show nuclear co-
localization only with those apoptin mutants that accumulated in the nucleus (27). Thus, 
the study proposed that interaction between Akt and Apoptin caused them to be 
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transported to the nucleus, where Akt activates CDK2. This activation leads to Apoptin 
phosphorylation triggering tumor-specific apoptosis (27). 
Besides focusing on the roles of NES and multimerization domains in Apoptin’s overall 
activity as a potential anti-cancer therapy, it is equally important to investigate other 
aspects within the protein that might also play a role in its function. Aforementioned 
studies are some examples of many possibilities that are worth investigating in order to 
better understand the biochemistry of Apoptin’s behavior as a tumor-selective killer. 
  
 
 
 
 
 
  
34 
 
Figures 
 
 
Figure 1: This is an image of 0.9% agarose gel used to assay ApI37A and ApI40A 
mutants (from pGBKT7 vector) via electrophoresis. Lane 1 was loaded with 10ul of 
marker; lanes 3 and 4 were loaded with 20ul of ApI37A mutant and lanes 7 and 8 with 
20ul of ApI40A mutant. Both of these mutants were restricted using enzymes BamH1 
and Nco1. The drop outs observed in all of these four lanes are representative of their 
respective mutation inserts. 
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Figure 2: This is an image of 0.9% agarose gel used to assay via electrophoresis the 
pACT2 vector for the purpose of ligating DNA mutants into it. Lane 1 was loaded with 
10ul of marker while lanes 3, 5, 7 and 9 were loaded with 20ul of restriction digests 
containing parent vector only, parent vector with Nco1 only, parent vector with BamH1 
only and parent vector with both the enzymes respectively. The excised portion of 
vector from lane 9 was used for ligation purposes. 
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Figure 3: Confocal fluorescence microscopy pictures of H1299 cells    
transfected with mutant ApL43A Apoptin tagged with GFP and wildtype 
Apoptin tagged with dsRed. DAPI is a general nuclear stain. 
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Figure 4: Confocal fluorescence microscopy pictures of H1299 cells 
transfected with mutant ApL44A Apoptin tagged with GFP and 
wildtype Apoptin tagged with dsRed. DAPI is a general nuclear 
stain.  
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